{"id":5575,"date":"2021-03-26T12:46:18","date_gmt":"2021-03-26T11:46:18","guid":{"rendered":"https:\/\/services.cbmed.at\/html\/old\/?p=5575"},"modified":"2021-03-26T12:46:18","modified_gmt":"2021-03-26T11:46:18","slug":"liquidbiopsy","status":"publish","type":"post","link":"https:\/\/services.cbmed.at\/html\/old\/?p=5575","title":{"rendered":"Liquid biopsy for precision oncology"},"content":{"rendered":"
\n

Liquid biopsy for precision oncology<\/h2>\n

<\/h4>\n

<\/h4>\n

Liquid biopsy is a non-invasive way for monitoring a cancer disease, or evaluating treatment response. CBmed has a focus on liquid biopsies, thereby implementing CEN\/ISO standards, developing assays and following a multi-analyte approach.<\/h4>\n<\/div>\n
<\/div>\n
\n

\u00a0Liquid biopsy essentially stands for the blood-based analysis of circulating tumor cells (CTCs) or circulating tumor derived nucleic acids. For instance, if a tumor is growing, it can shed tumor cells into blood, which are then called CTC. The tumor can also shed circulating tumor DNA into blood, which is then called ctDNA. Both entities are commonly summarized as liquid biopsy, since they contain the same information as a tumor tissue itself. Like traditional biopsy, this type of technique has the potential to be used as a diagnostic- and monitoring tool for diseases such as cancer. So far, the gold standard is a tissue biopsy, where a part of the tumor is retrieved by a needle biopsy in order to analyse it further under the microscope or by molecular diagnostic approaches. With liquid biopsies, a blood sample is taken to isolate CTCs or ctDNA, which allows to reconstruct the genome of the tumor, amongst other parameters.<\/p>\n<\/div>\n

<\/div>\n<\/div><\/section>\n
<\/span><\/span><\/div>\n